Cite

    Gupta, N. et al. (2016). A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis. British journal of haematology. pp. 748-759. [Online].